Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 and 50mg in Asia Pacific Adults With Type 2 Diabetes (GRAND-307)
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, 24-week Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 and 50mg Compared With Placebo in Asia Pacific Subjects With Type 2 Diabetes
Sponsor: Takeda
Terminated
Due to potential concerns about liver safety (See Detailed Description)
Other terminated trials from Takeda
Other Type 2 Diabetes Mellitus trials with similar outcome
Listed as NCT01647542, this PHASE3 trial focuses on Type 2 Diabetes Mellitus and remains terminated or withdrawn. Sponsored by Takeda, it has been updated 7 times since 2012, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
7 versions recorded-
Dec 2025 — Present [monthly]
Terminated PHASE3
-
Sep 2025 — Dec 2025 [monthly]
Terminated PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE3
▶ Show 2 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE3
-
Jan 2017 — Jun 2018 [monthly]
Terminated PHASE3
First recorded
Oct 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Takeda
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Auckland, New Zealand , Beijing, China , Beijing,P.R., China , Brookvale, Australia , Changchun, China , Changchun City, Jilin Province, China , Changsha, China , Chengdu, China , Chenzhou, China , Chongqing, China and 34 more locations